Trials: Genitourinary Cancer

Disease sites included: Adrenal, Bladder, Kidney, Penile, Prostate, Testicular

You are here:

Find a Clinical Trial
Genitourinary Cancer

NCT00969111 – GU010-18 Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy

November 15, 2024

NCT03609216 – A031701 A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

July 24, 2024

NCT03609216 – A031701 A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

December 6, 2024

NCT03678025 – S1802 “Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

June 20, 2024

NCT04134260 – NRG-GU008 Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE) INtensifying treatment for NOde positive prostate cancer by Varying the hormonal Therapy

July 24, 2024

NCT04513717 – NRG GU009 – Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)

July 24, 2024

NCT05050084 – NRG GU010 “Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)”

July 24, 2024

NCT05327686 – NRG-GU012 – Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

July 24, 2024

NCT05411081 – S2200, A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)

July 24, 2024

NCT05946213 – NRG-GU013, “The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer”

July 24, 2024

NCT06044025 – A feasibility Study Evaluating a Role for Maintenance therapy in Patients with Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

June 20, 2024